One of the questions we get asked frequently at Juventas Wellness is how GLP-1 medications affect cravings. Most people are familiar with their role in weight loss and appetite control, but what many don’t realize is that researchers are now exploring another interesting possibility: GLP-1 medications may also influence cravings for things beyond food, including alcohol.
This is an exciting area of emerging research and another example of why we know GLP-1 medications are about more than weight loss. Their effects on appetite, metabolism, and the brain’s reward system are creating new conversations about how these medications may support overall health.
Let’s look at what researchers are discovering and what it could mean for people taking GLP-1 medications.
To understand why GLP-1 medications may affect cravings, it helps to understand how they work.
GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the body. It plays an important role in regulating blood sugar, appetite, digestion, and feelings of fullness.
Medications such as Tirzepatide or Semaglutide mimic the action of this hormone. They help regulate appetite, slow stomach emptying, and influence signals between the digestive system and the brain that affect hunger and satiety.
But there is another piece of the puzzle.
GLP-1 receptors are also found in areas of the brain involved in motivation, reward, and reinforcement. These pathways help explain why certain foods, beverages, and other experiences can create strong urges or feelings of anticipation.
Researchers believe that GLP-1 medications may influence some of these reward pathways, potentially making certain cravings feel less intense or less compelling.
Many people describe this experience as a reduction in “food noise.” Food may not occupy as much mental space throughout the day, and the constant urge to snack or think about the next meal may become less noticeable.
Researchers are now asking whether a similar effect may occur with other rewarding substances, particularly alcohol.
This is where things get particularly interesting.
Physicians have increasingly heard patients describe changes in their relationship with alcohol after starting GLP-1 medications. Some report that they simply don’t think about drinking as much. Others say that when they do have a drink, they don’t feel the same desire to continue.
These observations have prompted researchers to investigate whether GLP-1 medications could have a role in reducing alcohol cravings.
A 2026 National Survey Found Meaningful Changes
A study published in JAMA Psychiatry on October 14, 2026, examined alcohol consumption patterns among people who had used GLP-1 medications.
Researchers surveyed 2,009 US adults. Of the participants who were drinking alcohol when they started a GLP-1 medication, 242 provided information about changes in their drinking habits.
The findings were interesting:
The findings were even more notable among individuals who screened positive for potentially unhealthy alcohol use before starting treatment. In that group, 54.1% reported drinking less.
This was a survey based on patient-reported experiences, not a controlled clinical trial. Therefore, it cannot establish that GLP-1 medications directly caused the reduction in alcohol consumption.
Still, it provides an important look at what people are reporting in everyday life and supports the need for additional research.
Clinical Trials Are Adding to the Evidence
The research is moving beyond patient anecdotes and surveys.
A randomized clinical trial published in JAMA Psychiatry in 2025 evaluated semaglutide in 48 adults with alcohol use disorder over nine weeks.
Researchers found that participants receiving semaglutide experienced reductions in weekly alcohol cravings and the amount of alcohol consumed per drinking occasion compared with those receiving placebo. Not every measure of alcohol consumption changed significantly, but the findings were encouraging enough to support larger clinical trials.
Another study published in The Lancet in May 2026 examined 108 adults with both obesity and alcohol use disorder. Participants received semaglutide or placebo alongside cognitive behavioral therapy.
The semaglutide group experienced a greater reduction in heavy drinking days over the 26-week study period compared with the placebo group.
A separate randomized trial published in the American Journal of Psychiatry in July 2026 examined oral semaglutide in 50 adults with moderate to severe alcohol use disorder. Although the primary laboratory-based measure of alcohol craving did not differ significantly between groups, researchers observed reductions in heavy drinking days, drinks per drinking day, and naturally occurring alcohol cravings.
Taken together, these studies suggest that GLP-1 medications may influence alcohol-related reward and craving pathways. However, the trials were relatively small and short, and additional research is needed to understand which individuals might benefit and how these medications should be used.
The brain’s reward system plays an important role in both eating behavior and alcohol consumption.
When we eat something enjoyable or participate in an activity we find rewarding, the brain reinforces that experience. This can create anticipation and motivation to repeat it.
Alcohol also interacts with these reward pathways.
Researchers believe GLP-1 medications may influence some of the same brain circuits involved in these responses. By changing how the brain processes reward signals, these medications may reduce the intensity of certain urges.
This may help explain why some people report:
Not everyone experiences these changes, and the degree of response can vary considerably.
It is also important to understand that reducing cravings is not the same as treating alcohol use disorder. GLP-1 medications are not currently FDA-approved for alcohol use disorder, and they should not replace established addiction treatments or professional support.
At Juventas Wellness, we often talk about GLP-1 medications in the context of weight management, but their role in the body is much broader.
These medications interact with metabolic and hormonal pathways that influence several aspects of health.
Some of their established or well-studied effects include:
Blood sugar regulation: GLP-1 medications help the body release insulin in response to elevated blood glucose and reduce inappropriate glucagon secretion. This is one reason certain medications in this class are used to treat type 2 diabetes.
Appetite and satiety: They help regulate hunger signals and promote feelings of fullness, which can make it easier for some individuals to manage portion sizes and overall food intake.
Cardiometabolic health: Certain GLP-1 medications such as Tirzepatide have demonstrated cardiovascular benefits in specific populations, including reductions in major cardiovascular events among eligible patients. The benefits depend on the medication, the individual’s health history, and the indication for treatment.
Potential effects on reward and cravings: Emerging research suggests GLP-1 medications may influence reward-related behaviors, including alcohol consumption. This is an area of active investigation rather than an established treatment indication.
These different effects remind us that metabolic health is connected to much more than body weight.
For additional information about how these medications work and the importance of physician oversight, explore our GLP-1 medical weight loss program and our article on GLP-1 medical supervision and safe weight management.
No. Just as weight loss results and appetite changes vary from person to person, changes in alcohol cravings are not universal.
Some people report a noticeable difference in their interest in alcohol, while others experience no change at all.
There are also important safety considerations.
For someone who regularly consumes large amounts of alcohol or has developed physical dependence, a sudden reduction in drinking can lead to alcohol withdrawal. Withdrawal can be medically dangerous and may require supervised treatment.
Anyone experiencing difficulty controlling alcohol use should discuss it with an appropriate healthcare professional rather than relying on a GLP-1 medication to manage the problem.
GLP-1 medications also have their own potential side effects and contraindications. Treatment decisions should take into account medical history, current medications, metabolic health, and individual goals. That’s why it’s so important to make sure you are using these medications with medical guidance.
For individuals in Cherry Creek, Arvada, Aurora, Littleton, and surrounding Denver Metro communities, these findings open an interesting conversation about the expanding role of metabolic health in preventative medicine.
At Juventas Wellness, we believe successful wellness care should look beyond a single number on the scale. Understanding appetite, metabolic function, cardiovascular risk, nutrition, and other health behaviors provides a more complete picture.
Our GLP-1 and peptide therapy programs are designed around physician oversight and individualized care. We consider each person’s health history, goals, and response to treatment rather than assuming one approach works for everyone.
We also recognize that nutrition remains an important part of treatment. When GLP-1 medications reduce appetite, maintaining adequate protein intake, hydration, and overall nutritional quality becomes especially important. Our GLP-1 nutrition guide offers practical information about eating well when appetite changes.
We are learning more about GLP-1 medications every year, and the research surrounding cravings is particularly interesting.
While these medications are well known for their effects on appetite, blood sugar, and weight management, emerging studies suggest they may also influence the brain’s reward pathways and potentially reduce alcohol cravings in some individuals.
This does not mean GLP-1 medications are a treatment for alcohol use disorder, or that everyone taking them will experience fewer cravings. More research is needed before their role in addiction treatment can be established.
What it does show is that GLP-1 medications may have effects beyond what we initially understood, and researchers are continuing to explore their potential role in broader metabolic and behavioral health.
At Juventas Wellness, we find this evolving research exciting because it reinforces something we have always believed: good healthcare should look at the whole person, not just their weight.
If you are interested in learning more about GLP-1 medications, their potential benefits, or whether physician-guided treatment may be appropriate for your health goals, we invite you to schedule a GLP-1 consultation with Juventas Wellness.
Our goal is to help you understand your options and make informed decisions about your long-term health.